
Izberite svojo etiketo
prikazano neposredno na vialiReta + Tesamorelin Blend
GLP-1
- Odprema iz Nemčije
Naročilo
- DHL s sledenjem
- Diskretna embalaža
Na prvi pogled
Reta + Tesamorelin Blend v številkah
Ključni podatki iz našega leksikona.
Celoten vnos v leksikonu- Type
- Injectable blendtriple agonist + GHRH analog
- Sizes
- 20 mg1 size in the shop
What studies show
All 4 sources in the lexiconRetatrutide phase 2 trial (obesity), 48 weeks, NEJM 2023 (opens in a new tab)
New England Journal of Medicine (PubMed PMID 37366315)Retatrutide systematic review + meta-analysis (878 patients), 2025 (opens in a new tab)
Proc (Bayl Univ Med Cent) (PubMed PMID 40291085)Tesamorelin phase 3 trial (visceral fat, HIV), 12 months (opens in a new tab)
J Acquir Immune Defic Syndr (PubMed PMID 20101189)
Za Reta + Tesamorelin Blend še ni laboratorijske analize. Glasujte zanjDajte testirati sami, mi plačamo polovicoVse laboratorijske analize
Znanje
Vse o Reta + Tesamorelin Blend
Podrobne informacije bodo kmalu na voljo.
Odmerjanje
Nalaganje podatkov o odmerjanju …
Priporočljivo zraven
Kaj potrebujete zraven
Bakteriostatska voda se samodejno doda v vašo košarico. Brizge in robčki z enim klikom.
Inzulinske brizge
10 kos. · 5.50 €
Alkoholni robčki
50 kos. · 10 €
Koliko vode?
Enote na brizgi za vašo velikost viale.
Odpri kalkulator →Is the Reta + Tesamorelin Blend approved or studied?
No. As of 26 October 2026 the registry ClinicalTrials.gov lists no trial with Retatrutide and tesamorelin together. Tesamorelin alone has been approved in the USA since 2010, Retatrutide is in phase 3 and not approved.
What is the catch with the fixed mix?
The two substances were studied on very different schedules: Retatrutide once a week, tesamorelin daily. In a 1:1 vial the ranges from both trial programmes cannot be matched at the same time. The entry therefore goes by the Retatrutide share.
What do the Retatrutide trials show?
In phase 2 body weight fell by 24.2 percent after 48 weeks at the highest study dose, by 2.1 percent on placebo. In phase 3 (TRIUMPH-1) it was 25.0 versus 3.9 percent after 80 weeks. A meta-analysis with 878 participants confirmed clear effects on weight and metabolic values.
What do the tesamorelin trials show?
In 806 patients with HIV and excess belly fat, visceral fat fell by 15.4 percent more than on placebo in 26 weeks, subcutaneous fat stayed nearly the same. IGF-1 rose, blood sugar stayed stable. Those who continued kept the effect to week 52.
Which side effects were seen with the components?
Retatrutide: mainly nausea, diarrhoea and other gastrointestinal effects, depending on the dose, plus a slight rise in heart rate. Tesamorelin: injection site reactions, joint and muscle pain, fluid retention and tingling. There is no safety profile for the blend.
Which trials are still running?
Nine phase 3 trials of Retatrutide are running, the largest on heart and kidney events until 2029. The phase 3 trials of tesamorelin were completed years ago. No trial of the blend is listed in the registry.
Sorodno
Sorodni izdelki
Tirzepatide
Peptidi · GLP-1 in izguba maščobe GLP-1 in izguba maščobe
10 velikosti
Laboratorijsko testirano
= od 10 €/vialo
Retatrutide
Peptidi · GLP-1 in izguba maščobe GLP-1 in izguba maščobe
11 velikosti
Laboratorijsko testirano
= od 16 €/vialo
Semaglutide
Peptidi · GLP-1 in izguba maščobe GLP-1 in izguba maščobe
6 velikosti
Laboratorijsko testirano
= od 10 €/vialo
Mazdutide
Peptidi · GLP-1 in izguba maščobe GLP-1 in izguba maščobe
2 velikosti
= od 32 €/vialo
Reta + Tesamorelin Blend